While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in ...

As research continues, the role of semaglutide in cardiovascular care will likely expand, potentially transforming how we approach heart disease prevention in at-risk populations. With heart ...

Semaglutide can rapidly reduce heart attacks and other serious ... all SELECT patients had a history of heart disease, placing them at high risk. It is worth noting, they say, given their ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Landmark' data has revealed a popular weight loss medicine slashes the risk of heart attack, stroke or heart disease death ...

The drug, which contains the active ingredient semaglutide ... a clinical trial found it reduced the risk of having a heart attack, stroke or heart disease death by 37% in people with obesity ...